Lundbeck appoints European leaders
pharmafile | February 10, 2012 | News story | Medical Communications, Sales and Marketing | Cipralex, Lundbeck
Lundbeck has appointed two new regional vice presidents for European markets, in time for new drug launches.
João Rocha is to head up operations in most western Europe countries while Michael Quiqueran-Beaujeu will oversee markets in eastern Europe, as well as Turkey and Russia.
The company says the appointments will important strengthen its European organisation at a time when Lundbeck will be launching a number of new drugs that will continue to build the foundation of Lundbeck’s business.
Lundbeck needs new products to sell well to compensate for its biggest seller Cipralex/Lexapro (co-marketed with Forest in the US) which goes off patent in March.
The company has a new antidepressant LU21004, in co-development with Takeda which is expected to produce ‘make or break’ phase III data in the second quarter.
Lundbeck has also launched its new antipsychotic treatment Sycrest in its first European market in April 2011.
“Europe is still Lundbeck’s largest market, and with our growing drug portfolio and several new launches in the near future, it is important that we consolidate and strengthen our European organization,” says Marie-Laure Pochon, Lundbeck’s executive vice president for commercial operations.
“With our new structure and the appointment of João Rocha and Michael Quiqueran-Beaujeu, who both bring with them many years of experience and impressive results, I am convinced that we have a set-up that gives us the optimal conditions for success in developing and expanding the Lundbeck business.”
João Rocha has served as Lundbeck’s country manager in Brazil and regional vice president for Latin America. Among his achievements is making Lundbeck’s antidepressant Lexapro eighth best-selling drug in Brazil, and has made Lundbeck a central player in the Latin American pharmaceutical industry. João Rocha is a citizen of Brazil who worked for US companies Schering-Plough and Merck before he joined Lundbeck.
Michael Quiqueran-Beaujeu comes to Lundbeck from a position as senior vice president and general manager for Northern Europe at Genzyme. Since he took on the role of vice president there in 2004, first for Central Europe and then for Northern Europe, he has increased sales by more than fourfold in less than four years. Michael Quiqueran-Beaujeu is an Austrian citizen with more than 20 years of experience in the European pharma industry, and has worked for Sandoz, Hoffman-La Roche and Genzyme, among others.
Related Content
Otsuka and Lundbeck gain FDA approval for supplemental New Drug Application for dementia drug
Japan-based healthcare company Otsuka Pharmaceutical and Danish pharma company Lundbeck have announced that the US …
Lundbeck to restructure R&D, shedding up to 160 jobs
Danish neuroscience specialist Lundbeck has announced it will be implementing a restructure of its Research …
Lundbeck’s Vyepti secures US approval for migraine prevention
Lundbeck’s Vyepti (eptinezumab-jjmr) has secured approval from the FDA, it has emerged, for the prevention …
